Laurent Pharmaceuticals Inc.
355 Peel, Suite 503
13 articles with Laurent Pharmaceuticals Inc.
Laurent Pharmaceuticals Completes Patients Enrollment in Phase 2 Study of LAU-7b for the Treatment of COVID-19
Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing the first-in-class pro-resolving drug LAU-7b, today announces that it has completed the enrollment for its placebo-controlled Phase 2 RESOLUTION clinical study of hospitalized patients with COVID-19. The study, which enrolled 240 patients across Canada and United States, is expected to report top-line results in Q3 2021.
Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing first-in-class pro-resolving drug LAU-7b, today announces that the independent Data Safety Monitoring Board (DSMB) for the Phase 2 RESOLUTION study in hospitalized patients with COVID-19
Laurent Pharmaceuticals Receives Approval from FDA to Initiate its COVID-19 Phase 2 Clinical Trial in the United States
The Phase 2 study aims to evaluate the dual antiviral and inflammation-controlling effects of the company's LAU-7b oral drug candidate against COVID-19 infection
Company to test LAU-7b’s dual pro-resolving inflammation and antiviral properties against COVID-19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
4/13/2020It was a very busy week for clinical trial news. Here’s a look.
Laurent Pharmaceuticals to initiate world-first testing of LAU-7b in COVID-19 patients
LAU-7b is an oral drug acting on the resolution phase of the inflammation, with the potential to treat chronic pulmonary inflammation that leads to irreversible lung damage in patients with CF.
This adds to the US$ 5 million development award already made available by the Foundation.
Laurent Pharmaceuticals Welcomes New Investors and Announces Scientific Breakthrough with LAU-7b in Cystic Fibrosis
Laurent Pharmaceuticals Inc. today announced new financing led by Keiretsu Forum Mid-Atlantic, Anges Quebec and Anges Quebec Capital, with participation from existing investors RSJ Gradus, Aligo Innovation, and Cystic Fibrosis Canada. Members from other Keiretsu Forum chapters also invested, as well as a select group of new and existing private individuals.
Laurent Receives FDA And Health Canada Clearance To Initiate APPLAUD Phase II Clinical Study Of LAU-7b For The Treatment Of Cystic Fibrosis